Bosentan

Generic Name: Bosentan

Brand Names: Stayveer, Tracleer

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉N_₅O_₆S

CAS Number: 147536-97-8

Unique Ingredient Identifier: XUL93R30K2

Background: Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Indication: Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).

Associated Conditions: NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Endothelin Receptor Function and Acute Stress

Not Applicable

Active, not recruiting

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Bosentan

First Posted Date: 2014-04-16

Last Posted Date: 2024-01-31

Lead Sponsor: Augusta University

Target Recruit Count: 320

Registration Number: NCT02116335

Locations: 🇺🇸
Georgia Regents University, Augusta, Georgia, United States

Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients

Phase 2

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Symbicort turbuhaler
Drug: Bosentan

First Posted Date: 2014-03-20

Last Posted Date: 2014-03-20

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 40

Registration Number: NCT02093195

Locations: 🇨🇳
The first affiliated hospital of xi'an jiaotong university, Xian, Shaanxi, China
🇨🇳
The department of pulmonary and critical care medicine, Tangdou hospital, Xian, Shaanxi, China
🇨🇳
The department of pulmonary and critical care medicine, Xijing hospital, Xi'an, Shaanxi, China

and more 2 locations

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration

Phase 1

Conditions: Healthy Volunteers

Interventions: Drug: Udenafil/Bosentan
Drug: Udenafil
Drug: Bosentan

First Posted Date: 2013-08-27

Last Posted Date: 2014-01-09

Lead Sponsor: Dong-A Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT01929213

Locations: 🇰🇷
Severance Hospital Clinical Trial Center, Seoul, Korea, Republic of

Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE

Phase 2

Conditions: Pulmonary Arterial Hypertension
Congenital Heart Disease

Interventions: Drug: Placebo
Drug: Bosentan

First Posted Date: 2013-04-09

Last Posted Date: 2017-08-16

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 12

Registration Number: NCT01827059

Locations: 🇳🇱
Academic Medical Centre, Amsterdam, Noord-Holland, Netherlands

ET-blockade and Exercise Induced Blood Flow in T2DM

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Bosentan

First Posted Date: 2013-01-30

Last Posted Date: 2016-05-04

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 22

Registration Number: NCT01779596

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

ET-blockade and Exercise-induced Vascular Adaptations in T2DM

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Bosentan
Behavioral: Exercise

First Posted Date: 2013-01-30

Last Posted Date: 2016-05-05

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 19

Registration Number: NCT01779609

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease

Not Applicable

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: Antiaggregant therapy
Drug: Bosentan
Drug: Statins
Drug: Antihypertensive therapy

First Posted Date: 2012-11-30

Last Posted Date: 2012-11-30

Lead Sponsor: Hospital Universitario Getafe

Target Recruit Count: 30

Registration Number: NCT01738542

Locations: 🇪🇸
Hospital Universitario de Getafe, Getafe, Madrid, Spain

Bosentan and Pulmonary Endothelial Function

Not Applicable

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Bosentan

First Posted Date: 2012-11-04

Last Posted Date: 2016-10-19

Lead Sponsor: Prof David S Celermajer

Target Recruit Count: 8

Registration Number: NCT01721564

Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients

Phase 3

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Iloprost
Drug: Bosentan

First Posted Date: 2012-10-24

Last Posted Date: 2014-02-27

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 90

Registration Number: NCT01712997

Locations: 🇨🇳
The department of pulmonary and critical care medicine, Tangdu hospital, Xi'an, Shaanxi, China
🇨🇳
The department of pulmonary and critical care medicine, Xijing hospital, Xi'an, Shaanxi, China

Bosentan Therapy in Children With Functional Single Ventricle

Phase 2

Completed

Conditions: Congenital Heart Defects
Functional Single Ventricle

Interventions: Drug: Bosentan

First Posted Date: 2012-08-10

Last Posted Date: 2012-08-10

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 34

Registration Number: NCT01662037

Locations: 🇨🇳
Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy